<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">DOT1L Protein</th></tr>
<tr><td><strong>Protein Name</strong></td><td>Disruptor of Telomeric Silencing 1-like</td></tr>
<tr><td><strong>Gene</strong></td><td>[DOT1L](/genes/dot1l)</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[Q8TEZ3](https://www.uniprot.org/uniprot/Q8TEZ3)</td></tr>
<tr><td><strong>PDB ID</strong></td><td>3UVW, 4ER5, 5X3O</td></tr>
<tr><td><strong>Molecular Weight</strong></td><td>~190 kDa (1,677 amino acids)</td></tr>
<tr><td><strong>Subcellular Localization</strong></td><td>Nucleus (chromatin-associated)</td></tr>
<tr><td><strong>Protein Family</strong></td><td>Histone methyltransferase (non-SET family)</td></tr>
<tr><td><strong>Brain Expression</strong></td><td>High in cortex, hippocampus, and cerebellum</td></tr>
<tr><td><strong>Domain Architecture</strong></td><td>N-terminal chromatin-binding domain, C-terminal catalytic domain</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/ad" style="color:#ef9a9a">AD</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a>, <a href="/wiki/carcinoma" style="color:#ef9a9a">Carcinoma</a>, <a href="/wiki/covid" style="color:#ef9a9a">Covid</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">92 edges</a></td>
</tr>
</table>
</div>
<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">DOT1L Protein</th></tr>
<tr><td><strong>Protein Name</strong></td><td>Disruptor of Telomeric Silencing 1-like</td></tr>
<tr><td><strong>Gene</strong></td><td>[DOT1L](/genes/dot1l)</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[Q8TEZ3](https://www.uniprot.org/uniprot/Q8TEZ3)</td></tr>
<tr><td><strong>PDB ID</strong></td><td>3UVW, 4ER5, 5X3O</td></tr>
<tr><td><strong>Molecular Weight</strong></td><td>~190 kDa (1,677 amino acids)</td></tr>
<tr><td><strong>Subcellular Localization</strong></td><td>Nucleus (chromatin-associated)</td></tr>
<tr><td><strong>Protein Family</strong></td><td>Histone methyltransferase (non-SET family)</td></tr>
<tr><td><strong>Brain Expression</strong></td><td>High in cortex, hippocampus, and cerebellum</td></tr>
<tr><td><strong>Domain Architecture</strong></td><td>N-terminal chromatin-binding domain, C-terminal catalytic domain</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/ad" style="color:#ef9a9a">AD</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a>, <a href="/wiki/carcinoma" style="color:#ef9a9a">Carcinoma</a>, <a href="/wiki/covid" style="color:#ef9a9a">Covid</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">92 edges</a></td>
</tr>
</table>
</div>
DOT1L (Disruptor of Telomeric Silencing 1-like) is a unique histone methyltransferase that catalyzes the methylation of histone H3 at lysine 79 (H3K79)[@freitas2024]. Unlike the majority of histone methyltransferases that belong to the SET domain family, DOT1L represents a distinct class of methyltransferases with remarkable structural and functional properties. The enzyme adds mono-, di-, and trimethylation marks to H3K79, a modification that plays critical roles in transcriptional regulation, DNA damage response, cell cycle progression, and development[@kouzarides2007].
The discovery of DOT1L's involvement in MLL-rearranged leukemia has made it a major therapeutic target in oncology, with several DOT1L inhibitors currently in clinical development[@okada2005]. Beyond its well-established role in hematological malignancies, emerging evidence suggests that DOT1L and H3K79 methylation are crucial for proper neuronal development, synaptic plasticity, and cognitive function. Dysregulation of this epigenetic pathway has been implicated in Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions[@mukherjee2021; @wu2020].
This comprehensive page covers DOT1L's molecular structure, its normal functions in the nervous system, its dysregulation in neurodegenerative diseases, and its potential as a therapeutic target.
DOT1L is a large protein composed of 1,677 amino acids with a molecular weight of approximately 190 kDa. Its unique architecture distinguishes it from most other histone methyltransferases and underlies its distinctive catalytic mechanism.
DOT1L possesses a multi-domain structure that enables its diverse functional properties:
N-terminal Chromatin-binding Domain (aa 1-800):
DOT1L adopts a unique fold that distinguishes it from SET domain methyltransferases:
DOT1L activity is regulated by several post-translational modifications:
Phosphorylation:
DOT1L is expressed throughout the brain, with particularly high levels in the cerebral cortex, hippocampus, and cerebellum. Within neurons, DOT1L localizes to both the nucleus and cytoplasm, where it performs essential functions in development and plasticity.
H3K79 methylation by DOT1L is associated with actively transcribed genes:
Gene Activation:
DOT1L plays a critical role in the cellular response to DNA damage:
Checkpoint Activation:
DOT1L-mediated H3K79 methylation is increasingly recognized as important for synaptic plasticity and cognitive function:
Long-term Potentiation (LTP):
DOT1L is essential for proper brain development:
Neuronal Migration:
Dysregulation of DOT1L and H3K79 methylation has been implicated in several neurodegenerative diseases. The epigenetic alterations affect multiple aspects of neuronal function, from gene expression to DNA repair and protein homeostasis.
DOT1L and H3K79 methylation are altered in Alzheimer's disease brain:
Epigenetic Dysregulation:
Emerging evidence links DOT1L to Parkinson's disease pathology:
Expression Changes:
DOT1L-mediated epigenetic changes are increasingly recognized as a hallmark of brain aging:
Age-Associated Changes:
Huntington's Disease:
DOT1L interacts with numerous proteins to perform its cellular functions:
| Partner Protein | Interaction Type | Functional Consequence |
|-----------------|-------------------|------------------------|
| MLL1/MLL2 | Direct binding | Recruitment to specific gene loci |
| AF4/AF9/ENL | MLL fusion proteins | Leukemogenic transformation |
| p300/CBP | Acetyltransferase complex | Enhanced catalytic activity |
| DOT1L-associated proteins | Direct interaction | Chromatin targeting |
| Repair Protein | Interaction | Pathway |
|----------------|-------------|---------|
| 53BP1 | H3K79me-dependent | NHEJ repair |
| ATM | Phosphorylation cascade | DNA damage response |
| MDC1 | Direct binding | Checkpoint activation |
| Factor | Mechanism | Effect |
|--------|-----------|--------|
| RNA Pol II | Co-transcriptional | Elongation |
| TFIID | Direct interaction | Transcription initiation |
| SIRT1 | Deacetylase regulation | Activity modulation |
DOT1L represents a promising therapeutic target for both cancer and neurodegenerative diseases. The development of selective DOT1L inhibitors has progressed significantly in recent years.
Epizyme (EPZ-5676/Pinometostat):
Alzheimer's Disease:
Selectivity:
DOT1L Conditional Knockout: